Invivyd shares closed up about 5% to roughly $0.72, a rare green day after a weak three month run. Yet the headline story sits on the income statement. The latest trailing twelve month figures still show heavy losses, with net income from continuing operations firmly in the red and basic earnings per share negative. That gap between a flicker of optimism in the price and the ongoing loss profile sets up a clear tension for investors.

The key question now is whether the market is rewarding the growth pipeline too quickly while the company continues to burn cash at scale.

Is Invivyd at US$0.72 a deep discount to its estimated US$43.33 fair value, or a signal that losses and dilution still weigh heavily on the story? See how the valuation…